BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ting H, Deep G, Agarwal R. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J 2013;15:707-16. [PMID: 23588585 DOI: 10.1208/s12248-013-9486-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Johnson RP, Ratnacaram CK, Kumar L, Jose J. Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer. Drug Resist Updat 2022;64:100865. [PMID: 36099796 DOI: 10.1016/j.drup.2022.100865] [Reference Citation Analysis]
2 Jao H, Chang F, Cheng C, Liang H, Wang C, Lee H. Silybum marianum seed disrupts mitosis by reducing polo-like kinase 1 in breast cancer cells. Phytomedicine Plus 2022;2:100164. [DOI: 10.1016/j.phyplu.2021.100164] [Reference Citation Analysis]
3 Abdelaal G, Veuger S. Reversing oncogenic transformation with iron chelation. Oncotarget 2021;12:106-24. [PMID: 33520115 DOI: 10.18632/oncotarget.27866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kaipa JM, Starkuviene V, Erfle H, Eils R, Gladilin E. Transcriptome profiling reveals Silibinin dose-dependent response network in non-small lung cancer cells. PeerJ 2020;8:e10373. [PMID: 33362957 DOI: 10.7717/peerj.10373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Cardoso HJ, Carvalho TMA, Fonseca LRS, Figueira MI, Vaz CV, Socorro S. Revisiting prostate cancer metabolism: From metabolites to disease and therapy. Med Res Rev 2021;41:1499-538. [PMID: 33274768 DOI: 10.1002/med.21766] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tuli HS, Mittal S, Aggarwal D, Parashar G, Parashar NC, Upadhyay SK, Barwal TS, Jain A, Kaur G, Savla R, Sak K, Kumar M, Varol M, Iqubal A, Sharma AK. Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance. Semin Cancer Biol 2021;73:196-218. [PMID: 33130037 DOI: 10.1016/j.semcancer.2020.09.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
7 Upadhyay P, Bhattacharjee M, Bhattacharya S, Ahir M, Adhikary A, Patra P. Silymarin-Loaded, Lactobionic Acid-Conjugated Porous PLGA Nanoparticles Induce Apoptosis in Liver Cancer Cells. ACS Appl Bio Mater 2020;3:7178-92. [PMID: 35019376 DOI: 10.1021/acsabm.0c00987] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Mashhadi Akbar Boojar M, Mashhadi Akbar Boojar M, Golmohammad S. Overview of Silibinin anti-tumor effects. Journal of Herbal Medicine 2020;23:100375. [DOI: 10.1016/j.hermed.2020.100375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Jiang Y, Song H, Jiang L, Qiao Y, Yang D, Wang D, Li J. Silybin Prevents Prostate Cancer by Inhibited the ALDH1A1 Expression in the Retinol Metabolism Pathway. Front Cell Dev Biol 2020;8:574394. [PMID: 32984354 DOI: 10.3389/fcell.2020.574394] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
10 Sellam LS, Zappasodi R, Chettibi F, Djennaoui D, Yahi-Ait Mesbah N, Amir-Tidadini ZC, Touil-Boukoffa C, Ouahioune W, Merghoub T, Bourouba M. Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. Arch Biochem Biophys 2020;690:108479. [PMID: 32679194 DOI: 10.1016/j.abb.2020.108479] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
11 Dobiasová S, Řehořová K, Kučerová D, Biedermann D, Káňová K, Petrásková L, Koucká K, Václavíková R, Valentová K, Ruml T, Macek T, Křen V, Viktorová J. Multidrug Resistance Modulation Activity of Silybin Derivatives and Their Anti-inflammatory Potential. Antioxidants (Basel) 2020;9:E455. [PMID: 32466263 DOI: 10.3390/antiox9050455] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
12 Izzo S, Naponelli V, Bettuzzi S. Flavonoids as Epigenetic Modulators for Prostate Cancer Prevention. Nutrients 2020;12:E1010. [PMID: 32268584 DOI: 10.3390/nu12041010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
13 Pawar SK, Jaldappagari S. Intercalation of a flavonoid, silibinin into DNA base pairs: Experimental and theoretical approach. J Mol Recognit 2019;33. [DOI: 10.1002/jmr.2812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hosseinabadi T, Lorigooini Z, Tabarzad M, Salehi B, Rodrigues CF, Martins N, Sharifi‐rad J. Silymarin antiproliferative and apoptotic effects: Insights into its clinical impact in various types of cancer. Phytotherapy Research 2019;33:2849-61. [DOI: 10.1002/ptr.6470] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
15 Pop S, Enciu AM, Tarcomnicu I, Gille E, Tanase C. Phytochemicals in cancer prevention: modulating epigenetic alterations of DNA methylation. Phytochem Rev 2019;18:1005-24. [DOI: 10.1007/s11101-019-09627-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
16 Sherman B, Hernandez AM, Alhado M, Menge L, Price RS. Silibinin Differentially Decreases the Aggressive Cancer Phenotype in an In Vitro Model of Obesity and Prostate Cancer. Nutr Cancer 2020;72:333-42. [PMID: 31287731 DOI: 10.1080/01635581.2019.1633363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
17 Jahanafrooz Z, Motamed N, Rinner B, Mokhtarzadeh A, Baradaran B. Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator. Life Sci 2018;213:236-47. [PMID: 30308184 DOI: 10.1016/j.lfs.2018.10.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 7.5] [Reference Citation Analysis]
18 Oufi HG. The cytogenetic effects of silibinin alone and in combination with methotrexate in mouse bone marrow. European Journal of Pharmacology 2018;824:179-84. [DOI: 10.1016/j.ejphar.2018.02.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
19 Rizwanullah M, Amin S, Mir SR, Fakhri KU, Rizvi MMA. Phytochemical based nanomedicines against cancer: current status and future prospects. Journal of Drug Targeting 2018;26:731-52. [DOI: 10.1080/1061186x.2017.1408115] [Cited by in Crossref: 23] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
20 Bijak M, Synowiec E, Sitarek P, Sliwiński T, Saluk-Bijak J. Evaluation of the Cytotoxicity and Genotoxicity of Flavonolignans in Different Cellular Models. Nutrients 2017;9:E1356. [PMID: 29240674 DOI: 10.3390/nu9121356] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
21 Dilshara MG, Jayasooriya RGPT, Molagoda IMN, Jeong JW, Lee S, Park SR, Kim GY, Choi YH. Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca2+-CaMKII-Sp1 pathway. Oncotarget 2018;9:10324-42. [PMID: 29535810 DOI: 10.18632/oncotarget.23129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
22 Kuen CY, Fakurazi S, Othman SS, Masarudin MJ. Increased Loading, Efficacy and Sustained Release of Silibinin, a Poorly Soluble Drug Using Hydrophobically-Modified Chitosan Nanoparticles for Enhanced Delivery of Anticancer Drug Delivery Systems. Nanomaterials (Basel) 2017;7:E379. [PMID: 29117121 DOI: 10.3390/nano7110379] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
23 Tsaroucha AK, Valsami G, Kostomitsopoulos N, Lambropoulou M, Anagnostopoulos C, Christodoulou E, Falidas E, Betsou A, Pitiakoudis M, Simopoulos CE. Silibinin Effect on Fas/FasL, HMGB1, and CD45 Expressions in a Rat Model Subjected to Liver Ischemia-Reperfusion Injury. Journal of Investigative Surgery 2018;31:491-502. [DOI: 10.1080/08941939.2017.1360416] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
24 Amawi H, Hussein NA, Karthikeyan C, Manivannan E, Wisner A, Williams FE, Samuel T, Trivedi P, Ashby CR Jr, Tiwari AK. HM015k, a Novel Silybin Derivative, Multi-Targets Metastatic Ovarian Cancer Cells and Is Safe in Zebrafish Toxicity Studies. Front Pharmacol 2017;8:498. [PMID: 28824426 DOI: 10.3389/fphar.2017.00498] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
25 Javan Maasomi Z, Pilehvar Soltanahmadi Y, Dadashpour M, Alipour Sh, Abolhasani S, Zarghami N. Synergistic Anticancer Effects of Silibinin and Chrysin in T47D Breast Cancer Cells. Asian Pac J Cancer Prev 2017;18:1283-7. [PMID: 28610415 DOI: 10.22034/APJCP.2017.18.5.1283] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
26 DE Oliveira DT, Savio AL, Marcondes JP, Barros TM, Barbosa LC, Salvadori DM, DA Silva GN. Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status. J Biosci 2017;42:91-101. [PMID: 28229968 DOI: 10.1007/s12038-016-9654-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
27 Molavi O, Narimani F, Asiaee F, Sharifi S, Tarhriz V, Shayanfar A, Hejazi M, Lai R. Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy. Pharm Biol 2017;55:729-39. [PMID: 28027688 DOI: 10.1080/13880209.2016.1270972] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
28 Anestopoulos I, Sfakianos AP, Franco R, Chlichlia K, Panayiotidis MI, Kroll DJ, Pappa A. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma. Molecules 2016;22:E62. [PMID: 28042859 DOI: 10.3390/molecules22010062] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
29 Shukla SK, Dasgupta A, Mehla K, Gunda V, Vernucci E, Souchek J, Goode G, King R, Mishra A, Rai I. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Oncotarget. 2015;6:41146-41161. [PMID: 26510913 DOI: 10.18632/oncotarget.5843] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
30 Goswami DG, Tewari-Singh N, Agarwal R. Corneal toxicity induced by vesicating agents and effective treatment options. Ann N Y Acad Sci 2016;1374:193-201. [PMID: 27327041 DOI: 10.1111/nyas.13121] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
31 Chakrabarti M, Ray SK. Synergistic anti-tumor actions of luteolin and silibinin prevented cell migration and invasion and induced apoptosis in glioblastoma SNB19 cells and glioblastoma stem cells. Brain Research 2015;1629:85-93. [DOI: 10.1016/j.brainres.2015.10.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
32 Raina K, Kumar S, Dhar D, Agarwal R. Silibinin and colorectal cancer chemoprevention: a comprehensive review on mechanisms and efficacy. J Biomed Res 2016;30:452-65. [PMID: 27476880 DOI: 10.7555/JBR.30.20150111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
33 Nambiar DK, Rajamani P, Deep G, Jain AK, Agarwal R, Singh RP. Silibinin Preferentially Radiosensitizes Prostate Cancer by Inhibiting DNA Repair Signaling. Mol Cancer Ther 2015;14:2722-34. [PMID: 26516160 DOI: 10.1158/1535-7163.MCT-15-0348] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
34 Nambiar DK, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1. Oncotarget 2014;5:10017-33. [PMID: 25294820 DOI: 10.18632/oncotarget.2488] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
35 Molavi O, Samadi N, Wu C, Lavasanifar A, Lai R. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma. Leuk Lymphoma 2016;57:1154-62. [PMID: 26133723 DOI: 10.3109/10428194.2015.1068306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
36 Kalemci S, Topal Y, Celik SY, Yilmaz N, Beydilli H, Kosar MI, Dirican N, Altuntas I. Silibinin attenuates methotrexate-induced pulmonary injury by targeting oxidative stress. Exp Ther Med 2015;10:503-7. [PMID: 26622344 DOI: 10.3892/etm.2015.2542] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
37 Mastron JK, Siveen KS, Sethi G, Bishayee A. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review. Anti-Cancer Drugs 2015;26:475-86. [DOI: 10.1097/cad.0000000000000211] [Cited by in Crossref: 49] [Cited by in F6Publishing: 63] [Article Influence: 7.0] [Reference Citation Analysis]
38 Prajapati V, Kale RK, Singh RP. Silibinin Combination with Arsenic Strongly Inhibits Survival and Invasiveness of Human Prostate Carcinoma Cells. Nutrition and Cancer 2015;67:647-58. [DOI: 10.1080/01635581.2015.1019635] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
39 Bosland MC, Ozten N, Eskra JN, Mahmoud AM. A Perspective on Prostate Carcinogenesis and Chemoprevention. Curr Pharmacol Rep 2015;1:258-65. [PMID: 26442200 DOI: 10.1007/s40495-015-0031-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
40 Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, Thompson SK, Zollo M, Spano D, Dhawan P, Sliva D, Subbarayan PR, Sarkar M, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Ye L, Helferich WG, Yang X, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Nowsheen S, Pantano F, Santini D. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. Semin Cancer Biol. 2015;35 Suppl:S244-S275. [PMID: 25865774 DOI: 10.1016/j.semcancer.2015.03.008] [Cited by in Crossref: 243] [Cited by in F6Publishing: 274] [Article Influence: 34.7] [Reference Citation Analysis]
41 Surai PF. Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives. Antioxidants (Basel) 2015;4:204-47. [PMID: 26785346 DOI: 10.3390/antiox4010204] [Cited by in Crossref: 227] [Cited by in F6Publishing: 231] [Article Influence: 32.4] [Reference Citation Analysis]
42 Kellici TF, Ntountaniotis D, Leonis G, Chatziathanasiadou M, Chatzikonstantinou AV, Becker-baldus J, Glaubitz C, Tzakos AG, Viras K, Chatzigeorgiou P, Tzimas S, Kefala E, Valsami G, Archontaki H, Papadopoulos MG, Mavromoustakos T. Investigation of the Interactions of Silibinin with 2-Hydroxypropyl-β-cyclodextrin through Biophysical Techniques and Computational Methods. Mol Pharmaceutics 2015;12:954-65. [DOI: 10.1021/mp5008053] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
43 Macha MA, Krishn SR, Jahan R, Banerjee K, Batra SK, Jain M. Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer. Cancer Treat Rev 2015;41:277-88. [PMID: 25624117 DOI: 10.1016/j.ctrv.2015.01.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
44 Lin PH, Aronson W, Freedland SJ. Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med 2015;13:3. [PMID: 25573005 DOI: 10.1186/s12916-014-0234-y] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 10.7] [Reference Citation Analysis]
45 Ting H, Deep G, Agarwal C, Agarwal R. The strategies to control prostate cancer by chemoprevention approaches. Mutat Res 2014;760:1-15. [PMID: 24389535 DOI: 10.1016/j.mrfmmm.2013.12.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]